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1. Introduction
1.1. Beta cells (β-cells)
Beta cells are a type of cell in the pancreas located in the so-called islets of Langerhans. They
make up 65-80% of the cells in the islets.
The Islets diameter is about 50 to 300 micrometers. They are composed of several types of cells.
At least 70 percent are beta cells, which are localized in the core of the islet. These cells are sur‐
rounded by alpha cells that secrete glucagon, smaller numbers of delta cells that secrete soma‐
tostatin, and PP cells or F cells that secrete pancreatic polypeptide. All of the cells communicate
with each other through extracellular spaces and through gap junctions. This arrangement al‐
lows cellular products secreted from one cell type to influence the function of downstream
cells. As an example, insulin secreted from beta cells can suppress glucagon secretion.
A neurovascular bundle containing arterioles and sympathetic and parasympathetic nerves
enters each islet through the central core of beta cells. The arterioles branch to form capilla‐
ries that pass between the cells to the periphery of the islet and then enter the portal venous
circulation.
2. Beta cells functions
Insulin is synthesized as preproinsulin in the ribosomes of the rough endoplasmic reticulum
in the beta cells (fig 1). Preproinsulin is then cleaved to proinsulin, which is transported to
the Golgi apparatus where it is packaged into secretory granules located close to the cell
membrane. Proinsulin is cleaved into equimolar amounts of insulin and C-peptide in the se‐
cretory granules. The process of insulin secretion involves fusion of the secretory granules
with the cell membrane and exocytosis of insulin, C-peptide, and proinsulin
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Insulin is a hormone that controls the blood glucose concentration. The liver maintains the
base-line glucose level, but the beta cells can respond quickly to spikes in blood glucose by
releasing some of its stored insulin while simultaneously producing more. The response
time is very quick.
Figure 1 Mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining.
Glucagon is labeled in red and the nuclei in blue
Apart from insulin, beta cells release C-peptide, a consequence of insulin production, into
the bloodstream in equimolar amounts. C-peptide helps to prevent neuropathy and other
symptoms of diabetes related to vascular deterioration.Measuring the levels of C-peptide
can give a practitioner an idea of the viable beta cell mass.
Beta-cells also produce amylin, also known as IAPP, islet amyloid polypeptide. Amylin
functions as part of the endocrine pancreas and contributes to glycemic control. Amylin's
metabolic function is now somewhat well characterized as an inhibitor of the appearance of
nutrient [especially glucose] in the plasma. Thus, it functions as a synergistic partner to in‐
sulin. Whereas insulin regulates long-term food intake, increased amylin decreases food in‐
take in the short term.
GABA (γ amino butyric acid) is produced by pancreatic beta cell. GABA released from beta
cells can act on GABA Areceptor in the α cells, causing membrane hyperpolarization and
hence suppressing glucagon secretion. An impaired insulin-Akt-GABAA receptors glucagon
secretory pathway in the islet may be an underlying mechanism for unsuppressed glucagon
secretion, despite hyperglycemia, in diabetic subjects. Some studies demonstrated that beta
cells also express GABA A receptors, forming an autocrine GABA signaling system. Howev‐
er, the role of this autocrine GABA signaling in the regulation of beta cell functions remains
largely unknown.
Zinc is needed by over 300 enzyme systems.Some of those are involved with the metabolism
of blood sugar and are so important that a lack of zinc, in and of itself, can cause type I or
type II diabetes.
Zinc is highly concentrated in the insulin-secreting beta cells of our pancreas. Zinc can keep in‐
sulin molecules together in the beta cells.Beta cells must have zinc to function. In fact, beta cells
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contain their own special zinc transporter called zinc transporter 8 that enables beta cells to
take up zinc.Gene alterations in this zinc transporter are now known to cause type II diabetes
while type I diabetes is associated with antibodies against this zinc transporter (meaning the
immune system knocks out function of beta cells so they can’t produce insulin).
Zinc directly influences how insulin is produced and secreted by our beta cells. So the peo‐
ple with zinc deficiency can’t store and release insulin.Furthermore, zinc is self-protecting to
the beta cells.It has now been shown that zinc directly reduces the inflammatory signals that
damage the beta cells, a process that leads to type I diabetes.
3. Mechanisms of insulin secretion from beta cells
The secretion of insulin from pancreatic beta cells is a complex process involving the inte‐
gration and interaction of multiple external and internal stimuli. Thus, nutrients, hormones,
neurotransmitters, and drugs all activate or inhibit insulin secretion. The primary stimulus
for insulin release is the beta-cell response to changes in glucose concentration. Normally,
glucose induces a biphasic pattern of insulin release. First-phase insulin release occurs with‐
in the first few minutes after exposure to an elevated glucose level; this is followed by a
more permanent second phase of insulin release. Of particular importance is the observation
that first-phase insulin secretion is lost in patients with type 2 diabetes. Thus, molecular
mechanisms involved in phasic insulin secretion are important. This processes discussed as
follow (fig 2).
Figure 2. The beta cell structure
A widely accepted sequence of events involved in glucose-induced insulin secretion is as
follows:
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1. Glucose is transported into beta cells through facilitated diffusion of GLUT2 glucose
transporters.
2. Intracellular glucose is metabolized to ATP.
3. Elevation in the ATP/ADP ratio induces closure of cell-surface ATP-sensitive K+
(KATP) channels, leading to cell membrane depolarization.
4. Cell-surface voltage-dependent Ca2+ channels (VDCC) are opened, facilitating extracel‐
lular Ca2+ influx into the beta cell.
5. A rise in free cytosolic Ca2+ triggers the exocytosis of insulin.
It is understood that glucose stimulates insulin secretion in the pancreatic beta cell by means of
a synergistic interaction between at least two signaling pathways. In the K (ATP) channel-de‐
pendent pathway, glucose stimulation increases the entry of extrinsic Ca2+ through voltage-
gated  channels  by  closure  of  the  K  (ATP)  channels  and  depolarization  of  the  beta  cell
membrane. The resulting increase in intracellular Ca2+ stimulates insulin exocytosis. While in
the GTP-dependent pathway, intracellular Ca2+ is elevated by GTP-dependent proteins and
augments the Ca2+-stimulated release. Secretagogues and insulin secretion inhibitors act at in‐
termediate steps of these signaling pathways and influence the process of insulin exocytosis.
Several researchers have investigated this intricate mode of known secretagogue action using
isolated islets as an in vitro model. To quote a few; imidazoline antagonists of alpha 2-adrenore‐
ceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic
beta cells. Some researchers have evaluated the properties of sulphonylurea receptors (SUR) of
human islets of Langerhans. They studied the binding affinity of various oral hypoglycaemic
agents to the receptor and also tested insulinotropic action of the drugs on intact human islets.
This binding potency order was parallel with the insulinotropic potency of the evaluated com‐
pounds. Some investigators have shown an insulinotropic effect of Triglitazone (CS-045) and
have shown its mode of action to be distinct from glibenclamide (a sulphonylurea drug).
A-4166, a derivative of D-phenylalanine, evokes a rapid and short-lived hypoglycaemic action
in vivo. It has been shown to act via the tolbutamide binding sites14. Some studies showed
S21403, a meglitinide analogue to be a novel insulinotropic tool in the treatment of type 2 diabe‐
tes, as it affected cationic fluxes and the drugs secretary responses displayed favourable time
course of prompt, and not unduly prolonged, activation of beta cells. Some studies demon‐
strated that tetracaine (an anaesthetic) stimulates insulin secretion by release of intracellular
calcium and for the first time elucidated the role of intracellular calcium stores in stimulus-se‐
cretion coupling in the pancreatic beta cells. JTT-608, is a nonsulphonylurea oral hypoglycae‐
mic agent which stimulates insulin release at elevated but not low glucose concentrations by
evoking PKA-mediated Ca2+ influx.
4. The importance of KATP channels
The KATP channels play an integral role in glucose-stimulated insulin secretion by serving
as the transducer of a glucose-generated metabolic signal (ie, ATP) to cell electrical activity
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(membrane depolarization). Thus, like neurons, beta cells are electrically excitable and capa‐
ble of generating Ca2+ action potentials that are important in synchronizing islet cell activity
and insulin release. In addition to being signal targets for glucose, KATP channels are the
targets for sulfonylureas, which are commonly prescribed oral agents in the treatment of
type 2 diabetes. The sulfonylureas, like glucose, induce closure of KATP channels and stim‐
ulate insulin secretion.
The beta-cell KATP channel is a complex octameric unit of 2 different proteins: the sulfony‐
lurea receptor (SUR-1) and an inward rectifier (Kir6.2). The sulfonylurea receptor belongs to
a superfamily of ATP-binding cassette proteins and contains the binding site for sulfonylur‐
ea drugs and nucleotides. The inward rectifier represents the K+ conducting pore and is also
regulated by ATP. It is interesting that KATP channels are present in other tissues of the
body, including heart (SUR-2A/Kir 6.2), smooth muscle (SUR-2B/Kir 6.2), and brain
(SUR-1/Kir 6.2). Recently, Mark L. Evans, MD, Yale University Medical School, New Haven,
Connecticut, and colleagues have suggested that glucose sensing in the brain during hypo‐
glycemia may be mediated by KATP channels located in brain hypothalamic neurons. Thus,
these molecules may also serve as new therapeutic targets for the restoration of impaired
hypoglycemia awareness and glucose counterregulation in type 1 diabetes.
5. Voltage-dependent Ca2+ channels: Novel regulators
Extracellular Ca2+ influx through L-type voltage-dependent Ca2+ channels (VDCC) raises
free cytoplasmic Ca2+ levels and triggers insulin secretion. The structure of the VDCC is
complex and consists of 5 subunits: alpha1, alpha2, beta, gamma, and delta units. The alpha
subunit constitutes the ion-conducting pore, whereas the other units serve a regulatory role.
Previous work has identified that isoforms of alpha1 subunits interact with exocytotic pro‐
teins. More recently, using the yeast hybrid screening method, a novel protein, Kir-GEM, in‐
teracting with the beta3 isoform of the VDCC, has been identified by Seino and colleagues.
Furthermore, it has been determined that Kir-GEM inhibits alpha ionic activity and prevents
cell-surface expression of alpha subunits. The investigators have proposed that in the pres‐
ence of Ca2+, Kir-GEM binds to the beta isoform, and this interaction interferes in the traf‐
ficking or translocation of alpha subunits to the plasma membrane. The relevance of Kir-
GEM in insulin secretion was made evident by its attenuation of glucose-stimulated Ca2+
increases and C-peptide secretion in an insulin-secreting cell line.
The potential therapeutic role of Kir-GEM lies in the inhibitory effects on VDCC activity that
may serve to protect beta cells from overstimulation and subsequent failure, which is part of
the disease etiology of type 2 diabetes.
6. Novel cAMP signaling pathways of insulin release
The incretins are another set of factors that are important hormonal regulators of insulin secre‐
tion. The incretins are polypeptide hormones released in the gut after a meal that potentiate in‐
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sulin secretion in a glucose-dependent manner. Due to their dependence on ambient glucose
for action, they are emerging as important new therapeutic agents to promote insulin secretion
without accompanying hypoglycemia (a common complication of sulfonylurea treatment).
Unlike sulfonylureas, incretins act by activating Gs (a G-protein that activates adenylyl cy‐
clase) to increase cAMP in beta cells. cAmp, like ATP, is an important signal that regulates
insulin release. Typically, the main mechanism of action of cAMP is by activation of an en‐
zyme called protein kinase A (PKA) that, in turn, phosphorylates other substrates to turn on
(or off) vital cell functions. Using a biochemical assay called the yeast hybrid screening
method to identify and isolate new proteins, some researchers identified a novel protein,
cAMP-GEF II, a cAMP sensor (cAMPS) that forms a complex with other intracellular pro‐
teins (Rim2 and Rab3) to directly regulate insulin exocytosis. Then, using molecular reagents
that antagonize the effects of cAMPS, they observed that incretin-potentiated insulin secre‐
tion is attenuated. These results provide a mechanism whereby cAMP can directly promote
exocytosis of insulin granules without activation of PKA (ie, a PKA-independent pathway),
and thereby provide additional molecular targets for therapeutic intervention.
7. Beta cell dysfunction and apoptosis
Type one diabetes: Islet beta-cells are almost completely destroyed when patients with type
1 diabetes are diagnosed. Type 1 diabetes occurs when the bodies own immune system de‐
stroys the beta cells. Some people develop a type of diabetes – called secondary diabetes --
which is similar to type 1 diabetes, but the beta cells are not destroyed by the immune
system but by some other factor, such as cystic fibrosis or pancreatic surgery.
Type two diabetes: Defects in insulin action and insulin secretion are both present in type 2
diabetes, and both are believed to be genetically predetermined. In the absence of a defect in
beta-cell function, individuals can compensate indefinitely for insulin resistance with appro‐
priate hyperinsulinemia, as observed even in obese populations. Both insulin secretion and
insulin action are impaired in type 2 diabetes. However, when allowance is made for the hy‐
perglycaemia and the fact that glucose stimulates insulin secretion, it becomes apparent that
the insulin levels in diabetic patients are lower than in healthy controls and inadequate beta-
cell function therefore represents a key feature of the disease. Theoretically, the insulin se‐
cretory defect could result from either defects of beta-cell function or a reduction in beta-cell
mass. Most quantitative estimates indicate that type 2 diabetes associates with either no
change or < 30% reduction in beta-cell mass. Moreover, the secretion defect is more severe
than can be accounted for solely by the reduction in beta-cell mass. It therefore appears that
the insulin secretory defect in type 2 diabetes does not primarily result from insufficient be‐
ta-cell mass but rather from an impairment of insulin secretion.
8. Prevention of beta cell dysfunction and apoptosis
Islet beta-cells are almost completely destroyed when patients with type 1 diabetes are diag‐
nosed. To date, insulin substitute therapy is still one of the main treatments. The cure of
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type 1 diabetes requires beta-cell regeneration from islet cell precursors and prevention of
recurring autoimmunity. Therefore, beta-cell replacement, regeneration and proliferation
emerge as a new research focus on therapy for type 1 diabetes; however, its application is
limited by the shortage of pancreas donors. In-vitro expansion of human cadaveric islet beta
cells represents an attractive strategy for generation of abundant beta-like cells. Human beta
cells patent a very low proliferation capacity in vivo, and intact isolated islets cultured in
suspension do not proliferate, although they remain functional for months. When islets are
allowed to attach, limited replication of beta cells can be induced by growth factors or ex‐
tracellular matrix components before the beta-cell phenotype is lost. Previous accepting of
the determinants of tissue mass during adult life is still rudimentary. Insights into this prob‐
lem may suggest novel approaches for the treatment of neoplastic as well as degenerative
diseases. In the case of the pancreas, elucidating the mechanisms that govern β cell mass
will be important for the design of regenerative therapy for both type 1 and type 2 diabetes,
diseases characterized by an insufficient mass of β cells. It is clear that β cell mass increase
during pregnancy and in insulin-resistant states, but evidence on the ability of β cells to re‐
generate from a severe, diabetogenic injury is conflicting. Whereas autoimmune diabetes is
normally irreversible, recent evidence from both humans and rodents suggests that β cell
function (i.e., insulin production and the maintenance of glucose homeostasis) can partly re‐
cover if autoimmunity is blocked.
Islet beta-cell regeneration and development are controlled by many growth factors, espe‐
cially insulin-like growth factor-1 (IGF-1). Pancreatic islets produce Igf1 and Igf2, which
bind to specific receptors on β-cells. Igf1 has been shown to influence β-cell apoptosis, and
both Igf1 and Igf2 increase islet growth; Igf2 does so in a manner additive with fibroblast
growth factor 2. Some study showed that IGF-1 can protect beta-cells from the destruction of
apoptosis factors and promoting beta-cell survival and proliferation. Interleukin-1beta (IL-1
beta) is a potent pro-inflammatory cytokine that has been shown to inhibit islet beta cell
function as well as to activate Fas-mediated apoptosis in a nitric oxide-dependent manner.
Furthermore, this cytokine is effective in recruiting lymphocytes that mediate beta cell de‐
struction in type one diabetes. IGF-I has been shown to block IL-1beta actions in vitro.
Glucagon like peptide 1 (GLP-1) is a potent insulin secretagogue released by L-cells of the
distal large intestine in response to meal ingestion and, together with glucose-dependent in‐
sulinotropic polypeptide (GIP), account for 90% of the incretin effect. Type 2 diabetic pa‐
tients are characterized by severely impaired β-cell function, reduced plasma GLP-1
response to meal/glucose ingestion that correlates with reduced insulin secretion, and severe
β-cell resistance to the stimulatory effect of GLP-1 on insulin secretion. GLP-1 also inhibits
glucagon secretion, delays gastric emptying, and promotes weight loss by its appetite-sup‐
pressant effect. GLP-1 analogs also stimulate islet neogenesis and β-cell replication and in‐
hibit islet apoptosis. The gluco-incretin hormones GLP-1 and GIP can protect beta-cell
against apoptosis induced by cytokines or glucose and free fatty acids. Both hormones bind
to specific Gs-coupled receptors, which trigger cAMPformation. In beta-cells, basal cAMP
levels controls glucose competence, i.e., the magnitude of the insulin secretion response to a
given increase in extracellular glucose concentration. Increases in cAMP levels, for instance
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as stimulated by GLP-1 or GIP action, potentiate glucose-stimulated insulin secretion by
both protein kinase A (PKA)-dependent and independent mechanisms; they also stimulate
gene transcription through PKA dependent phosphorylation of the transcription factor
CREB. In beta-cells, increased cAMP levels also activate the MAP kinase cascade, leading to
rapid phosphorylation of Erk1/2. An activation of the PI3Kinase/Akt pathway is also ob‐
served. PI3kinase may be directly activated by the ßγ subunit of Gs, be secondary to transac‐
tivation of the EGF receptor by betacellulin, or may follow transcriptional induction of IRS-2
through the PKA/CREB pathway. The IRS- 2/PI3kinase/Akt pathway is known to have anti-
apoptotic effects; however, it is unclear why increased expression of IRS-2 leads to activa‐
tion of its signaling pathway. IRS-2 may be downstream of the insulin (IR) or IGF-1 (IGF-1R)
receptors. Studies of mice with beta-cell specific inactivation of either receptor indicated that
the insulin receptor was important for compensatory growth of the beta-cells in response to
insulin resistance whereas the IGF-1 receptor was involved in the control of glucose compe‐
tence. Although these properties make GLP-1 an ideal antidiabetic agent, it is rapidly
cleaved (T1/2 = 1–2 min) by dipeptidyl peptidase-4. GLP-1 enhances beta cell function with an
increase in the ability to secrete insulin and restore first phase insulin release. Our pervious
study showed that a novel GLP-1 analogue consisting of the fusion of active GLP-1 and IgG
heavy chain constant regions (GLP-1/IgG-fc) therapy can enhances beta cell mass. It also
could increase insulin secretion. Within the pancreas, GLP-1 expands β-cell mass via promo‐
tion of β-cell growth and reduction of β-cell death.
γ-Aminobutyric acid (GABA), a prominent inhibitory neurotransmitter, is present in high
concentrations in β-cells of islets of Langerhans. The GABA shunt enzymes, glutamate de‐
carboxylase (GAD) and GABA transaminase (GABA-T) have also been localized in islet β-
cells. With the recent demonstration that the 64,000-Mr antigen associated with insulin-
dependent diabetes mellitus is GAD, there isincreased interest in understanding the role of
GABA in islet functions. Only a small component of β-cell GABA is contained in insulin se‐
cretory granules, making it unlikely that GABA, co-released with insulin, is physiologically
significant. Our immunohistochemical study of GABA in β-cells of intact islets indicates that
GABA is associated with a vesicular compartment distinctly different from insulin secretory
granules. Whether this compartment represents a releasable pool of GABA has yet to be de‐
termined. GAD in β-cells is associated with a vesicular compartment, similar to the GABA
vesicles. In addition, GAD is found in a unique extensive tubular cisternal complex (GAD
complex). It is likely that the GABA-GAD vesicles are derived from this GAD-containing
complex. Physiological studies on the effect of extracellular GABA on islet hormonal secre‐
tion have had variable results. Effects of GABA on insulin, glucagon, and somatostatin se‐
cretion have been proposed. The most compelling evidence for GABA regulation of islet
hormone secretion comes from studies on somatostatin secretion, where it has an inhibitory
effect. Some researchers present new evidence demonstrating the presence of GABAergic
nerve cell bodies at the periphery of islets with numerous GABA-containing processes ex‐
tending into the islet mantle. This close association between GABAergic neurons and islet α-
and δ-cells strongly suggests that GABA inhibition of somatostatin and glucagon secretionis
mediated by these neurons. Intracellular β-cell GABAA and its metabolismmay have a role
in β-cell function. New evidence indicates that GABA shunt activity is involved in regula‐
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tion of insulin secretion. In addition, GABA or its metabolites may regulate proinsulin syn‐
thesis. These new observations provide insight into the complex nature of GABAergic
neurons and β-cell GABA in regulation of islet function. Our study showed that GABA ex‐
erts has protective and regenerative effects on islet beta cells and reverses diabetes. GABA
therapy increased beta cell proliferation and decreased beta cell apoptosis, which in turn in‐
crease beta cell mass and induced the reversal of hyperglycemia in the different kind of
mice. Our data suggest that GABA exerts has ani-inflammatory effects, and is directly inhib‐
itory to T cells and macrophages.
Magnesium deficiency has recently been proposed as a novel factor implicated in the patho‐
genesis of the diabetic complications. In our previous study we showed that oral chronic Mg
administration could improve islet structure and decrease the blood glucose.
Another potential treatment is the combination of two growth factors called gastrin and epider‐
mal growth factor (EGF), which has been shown to promote beta-cell regeneration in rats.
Many traditional treatments have been recommended in the alternative system of medicine for
treatment of diabetes mellitus and regeneration of beta cells such as Garlic, Teucriumpolium,
Cinnamon and Psidium guava leaves. Photochemical analysis of those herbs have revealed the
presence of flavonoids, which include quercetin and its derivatives. It is concluded that querce‐
tin, a flavonoid with antioxidant properties brings about the regeneration of the pancreatic is‐
lets and probably increases insulin release in streptozocin-induced diabetic rats.
Connective tissue growth factor (CTGF), to induce adult β cell mass expansion. Some study
showed that CTGF is required for embryonic β cell proliferation3, and that CTGF overex‐
pression in embryonic cells increases β cell proliferation and β cell mass.
The mouse pancreas develops from ventral and dorsal evaginations of the posterior foregut
endoderm at embryonic day, a process dependent on the transcription factors Pdx1 and
Ptf1. Differentiation of all pancreatic endocrine cell types (α, β, Δ and PP) is dependent on
the transcription factor, neurogenin 3 (Ngn3). Ngn3 expression is controlled by a variety of
factors, including the Notch signaling pathway and the transcriptional regulators pancreatic
and duodenal homeobox 1 (Pdx1), SRY-box 9 (Sox9) and hepatic nuclear factor 6 (Hnf6). Al‐
though β cell neogenesis begins, these early insulin-positive cells do not contribute to ma‐
ture islets. Instead, endocrine cells that will go on to contribute to the mature islets begin to
differentiate period known as the secondary transition. Some transcription factors critically
involved in β cell differentiation include NK2 homeobox 2 (Nkx2.2), Nkx6.1, islet 1 (Isl-1),
neuronal differentiation 1 (NeuroD1), motor neuron and pancreas homeobox 1(Mnx1),
paired box gene 4 (Pax4) and Pdx1.
In adults, physiological stimuli can enhance β cell proliferation during development. Al‐
though several factors have been identified that play a role in the regulation of embryonic
and neonatal β cell proliferation. One cell cycle regulator that does play a role in embryonic
β cell proliferation is the cell cycle inhibitor, p27Kip1. Inactivation of p27Kip1 during em‐
bryogenesis results in an increase in β cell proliferation and subsequently β cell mass. There
was no change, however, in early postnatal β cell proliferation, suggesting that p27Kip1 is
not crucial to postnatal proliferation.
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As mentioned above Pdx1expressed in multipotent pancreatic progenitors in the early
stages of pancreas development, but, Pdx1 expression becomes enhanced in insulin-positive
cells and is found at only low levels in exocrine cells. This expression pattern is maintained
into adulthood and Pdx1 plays a critical rolein maintenance of the mature β cell phenotype.
Inactivation of Pdx1 in embryonic insulin-expressing cells results in a dramatic decrease in β
cell proliferation at late gestation, leading to decreased β cell mass at birth and early onset
diabetes. Two large Maf (musculoaponeuroticfibrosarcoma oncogene homolog) transcrip‐
tion factors that are closely related to one another, MafA and MafB, are critical for β cell dif‐
ferentiation and embryonic Pdx1 expression22 and therefore may have an indirect effect on
embryonic β cell replication.
Inactivation of the eIF2α endoplasmic reticulum resident kinase, PERK (proteinkinase RNA-
like endoplasmic reticulum kinase), specifically in embryonic β cells (PERKΔbeta) results in
a 2-fold decrease in β cell proliferation, which persists through postnatal day (P).
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